title: Cardiovascular risk factors in patients on long-term treatment with nevirapine- or efavirenz-based regimens.
abstract: OBJECTIVE
  The aim of this study was to evaluate the cardiovascular risk among patients treated for more than 5 years with regimens based on nevirapine or efavirenz.
  
  
  METHODS
  A total of 276 patients were retrospectively evaluated, 156 of whom were treated with nevirapine and 120 with efavirenz, by examining traditional risk factors and detecting the presence of subclinical carotid lesions with colour-Doppler ultrasonography.
  
  
  RESULTS
  When comparing the data at baseline and follow-up in the nevirapine group, total cholesterol, low-density lipoprotein cholesterol (LDLc) and triglycerides showed a significant decrease, while high-density lipoprotein cholesterol increased. Ultrasound data, obtained in a subgroup of 67 patients, did not show significant changes for those treated with nevirapine. In the efavirenz group, total cholesterol, LDLc, triglycerides, glycaemia, body mass index and the number of patients with a pathological ultrasound significantly increased. When comparing the two groups at baseline and follow-up, nevirapine patients had significantly higher values of total cholesterol, LDLc and triglycerides at baseline, while total cholesterol and LDLc differed non-significantly at follow-up; triglycerides became significantly lower in the nevirapine arm with respect to the efavirenz group. Glycaemia was comparable between the two groups at baseline, while it was significantly lower in the nevirapine group at follow-up. The number of pathological ultrasound findings was significantly higher in the efavirenz group at follow-up.
  
  
  CONCLUSIONS
  Patients treated with nevirapine demonstrated a better lipid and glucose profile and a lower tendency to develop subclinical atherosclerotic lesions.
authors.affiliation: Institute of Infectious Diseases, Policlinico, University of Bari, Bari, Italy. p_maggi@yahoo.com
authors.forename: Paolo
authors.initials: P
authors.lastname: Maggi
authors.forename: Chiara
authors.initials: C
authors.lastname: Bellacosa
authors.forename: Valentina
authors.initials: V
authors.lastname: Carito
authors.forename: Francesco
authors.initials: F
authors.lastname: Perilli
authors.forename: Antonio
authors.initials: A
authors.lastname: Lillo
authors.forename: Anna
authors.initials: A
authors.lastname: Volpe
authors.forename: Giovanna
authors.initials: G
authors.lastname: Trillo
authors.forename: Domenico
authors.initials: D
authors.lastname: Angiletta
authors.forename: Guido
authors.initials: G
authors.lastname: Regina
authors.forename: Gioacchino
authors.initials: G
authors.lastname: Angarano
mesh_terms: D000328:Adult; D000368:Aged; D000480:Alkynes; D019380:Anti-HIV Agents / Q000009:adverse effects*; D048588:Benzoxazines / Q000008:administration & dosage*; D001774:Blood Chemical Analysis; D001786:Blood Glucose / Q000032:analysis; D002318:Cardiovascular Diseases / Q000139:chemically induced*; D002339:Carotid Arteries / Q000000981:diagnostic imaging / Q000473:pathology; D003521:Cyclopropanes; D005260:Female; D006801:Humans; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D019829:Nevirapine / Q000009:adverse effects*; D012189:Retrospective Studies; D018570:Risk Assessment; D018615:Ultrasonography, Doppler, Color
chemical_list: D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D001786:Blood Glucose; D003521:Cyclopropanes; D008055:Lipids; D019829:Nevirapine; C098320:efavirenz